Genomics: success or failure to deliver drug targets?
For decades, the entire pharmaceutical industry has focused on a limited number of drug targets. Owing to advances in molecular biology and genome technology at the beginning of the 1990s, discovery and isolation of a large number of genes from the human genome became feasible. This triggered a multi billion US dollars investment by both biotechnology and pharmaceutical companies to gain access to and patent as many potential drug targets as possible. Although the combined effort of publicly funded projects and private investments resulted in rapid identification of essentially all genes of the human genome, harnessing this information to enable drug discovery has turned out to be more challenging and time consuming than initially anticipated.
Bayer HealthCare AG, Pharma Research & Development, Wuppertal, Germany.
Ulrich Ak
UA
Betz
Ronald
R
Farquhar
Karl
K
Ziegelbauer
D000818:Animals; D015195:Drug Design; D004345:Drug Industry / Q000191:economics; D023281:Genomics; D006801:Humans; D018973:Intellectual Property